Immutep Limited (IMMP)
| Previous close | 2.8500 |
| Open | 2.8500 |
| Bid | 2.6800 x 100 |
| Ask | 2.7100 x 400 |
| Day's range | 2.6800 - 2.8500 |
| 52-week range | 1.5800 - 3.3400 |
| Volume | |
| Avg. volume | 236,820 |
| Market cap | 323.349M |
| Beta (5Y monthly) | 1.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Immutep successfully completes institutional placement and institutional component of entitlement offer
Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP) (Immutep or the Company) is pleased to announce the successful completion of its institutional placement (Placement) and the institutional component (Institutional Entitlement Offer) of its 1 for 16 pro rata accelerated non-renounceable entitlement offer (Entitlement Offer and, together with the Placement, the Offer) of new fully paid ordinary shares in Immutep (New Shares). The Placemen
- GlobeNewswire
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC)TACTI-004 Phase III trial will enrol approximately 750 patients regardless of PD-L1 expression in order to address the entire 1L NSCLC market eligible for anti-PD-1 therapyUnder the collaboration, Immutep will conduct the registrational TACTI-004 Phase III trial and MSD will supply KEYTRUDAImmutep retains commercial rights
- GlobeNewswire
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
Media Release Confirmed complete response in a patient with metastatic breast cancer refractory to several lines of therapy achieved during combination treatment with 90mg efti and paclitaxelOngoing complete response has been maintained since the patient started treatment with efti monotherapyEfti + paclitaxel combination continues to be well tolerated with a favourable safety profileFirst-ever 90mg dosing leads to higher maximum concentration of efti, as well as pharmacologically active level u
